BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 14, 2005
View Archived Issues
Gene Logic and Roche sign drug repositioning and development agreement
Read More
MedImmune licenses Eph-targeting peptides from Burnham Institute
Read More
New phase II trial investigates satraplatin plus Taxol for advanced NSCLC
Read More
BPI: A BCL6 peptide inhibitor that reactivates p53 tumor suppressor
Read More
Lilly reviews pipeline progression
Read More
Valomaciclovir rights revert to Medivir
Read More
LU-AA24530 enters the clinic
Read More
Pain Therapeutics discontinues further development of PTI-901
Read More
Further clinical assessment of lacosamide
Read More
Xopenex HFA now available
Read More
Orphan drug designation for Cethrin
Read More
New phase IIa study of oral RSD-1235 to prevent recurrence of atrial fibrillation
Read More
Phase II study of Epadel for Alzheimer's dementia finishes early
Read More
Compounds with potential in the treatment of HIV infection disclosed
Read More
Recent patents of agents for cardiovascular disorders
Read More
Ambrisentan PAH study shows significant improvement in six-minute walk distance
Read More
New candidates for sickle cell disease
Read More
The antiepileptic seletracetam inhibits HVA Ca2+ currents and intracellular Ca2+ elevations
Read More
Zanolimumab active, well tolerated in CD4+ peripheral T-cell lymphoma
Read More
Evidence of activity seen with KOS-953-trastuzumab in metastatic breast cancer patients
Read More
GW and Almirall announce European development and marketing agreement for Sativex
Read More
Increlex MAA filed in Europe
Read More
Data on SB-715992 in advanced or metastatic breast cancer reported
Read More
E-7389 monotherapy demonstrates potential in refractory breast cancer
Read More
KOS-862 active in anthracycline- and taxane-resistant breast cancer
Read More
Tocosol Paclitaxel evaluated as first-line treatment of metastatic breast cancer
Read More
Glivec submitted in Europe for adult patients with Ph+ ALL
Read More
NDA submission for arformoterol for COPD
Read More